Bosentan therapy in patients with pulmonary arterial hypertension: The relationship between improvements in 6 minute walk distance and quality of life

Respirology

Volumn 13, Issue 5, 2008, Pages 674-682

  Strange, Geoff ^a   Keogh, Anne M ^b   Williams, Trevor J ^c   Wlodarczyk, John ^d   Mcneil, Keith D ^e   Gabbay, Eli ^f  

^a Actelion Pharmaceuticals Australia   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d John Wlodarczyk Consulting Service   (United States)

^e THE PRINCE CHARLES HOSPITAL   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

6 minute walk distance; Bosentan; Hypertension; Pulmonary; Quality of life

Indexed keywords

BOSENTAN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL ASSESSMENT; CLINICAL TRIAL; CORRELATION ANALYSIS; FEMALE; FUNCTIONAL STATUS; GENERAL CONDITION IMPROVEMENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SHORT FORM 36; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WALKING; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICAL ENDURANCE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME; WALKING;

EID: 47149087329     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2008.01326.x     Document Type: Article

References (28)

1. Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004 126 : 1452 9.
2. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 1991 115 : 343 9.
3. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med. 2000 161 : 487 92.
4. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J. Heart Lung Transpl. 1996 15 : 100 5.
5. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N. Engl. J. Med. 1996 334 : 835 40.
6. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995 273 : 59 65.
7. Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J. Am. Coll. Cardiol. 2004 43 : 48S 55S.
8. Taichman DB, Shin J, Hud L, Archer-Chicko C, Kaplan S et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir. Res. 2005 6 : 92.
9. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 2002 347 : 322 9.
10. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 1996 334 : 296 302.
11. Archibald CJ, Auger WR, Fedullo PF, Channick RN, Kerr KM et al. Long-term outcome after pulmonary thromboendarterectomy. Am. J. Respir. Crit. Care Med. 1999 160 : 523 8.
12. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol. 2004 43 : 1149 53.
13. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2002 165 : 800 4.
14. Mikhail GW, Prasad SK, Li W, Rogers P, Chester AH et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur. Heart J. 2004 25 : 431 6.
15. Souza R, Jardim C, Martins B, Cortopassi F, Yaksic M et al. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Curr. Med. Res. Opin. 2005 21 : 907 11.
16. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2002 346 : 896 903.
17. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001 358 : 1119 23.
18. Galie N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2003 41 : 1380 6.
19. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003 124 : 247 54.
20. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur. Respir. J. 2005 25 : 244 9.
21. Keogh AM, McNeil K, Wlodarcyk J, Gabbay E, Williams TJ. Quality of life in pulmonary arterial hypertension: improved and maintained with bosentan. J. Heart Lung Transpl. 2007 26 : 181 7.
22. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can. Med. Assoc. J. 1985 132 : 919 23.
23. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992 30 : 473 83.
24. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2002 87 : 235 41.
25. O'Keefe ST, Lye M, Donnellan C, Carmichael DN. Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients. Heart 1998 80 : 377 82.
26. Hunt SM, McKenna SP, McEwen J, Williams J, Papp E. The Nottingham Health Profile: subjective health status and medical consultations. Soc. Sci. Med. [A 1981 15 : 221 9.
27. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am. Heart J. 1992 124 : 1017 25.
28. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990 16 : 199 208.